Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients
- 1Buck Artificial Intelligence Platform, the Buck Institute for Research on Aging, Novato, CA, USA; Stanford 1000 Immunomes Project, Stanford University School of
Abstract
Despite advances in clinical care, cardiovascular disease (CVD) remains the leading cause of disability and mortality worldwide. While age alone is a primary risk factor for CVD, accumulating evidence suggests the immune system influences the initiation and progression of CVD pathophysiology, particularly in heart failure with preserved ejection fraction (HFpEF) and atherosclerotic CVD (ASCVD). Here, using two independent cohorts of older adults, we develop a thirty-protein signature of age based on serum immune proteomics, which correlates with HFpEF and ASCVD risk and mortality (Immuno-Proteomic Age of Cardiovascular Etiology, iPACE). We find aging-related circulating immune proteins associated with ASCVD and HFpEF-specific resilience and susceptibility that may be used as potential prognostic, diagnostic, or therapeutic targets.
Related
- A neurofunctional signature of romantic love predicts rewards on social media, effects of oxytocin and drug-cue reactivity
- Plasma proteomics identifies an endoplasmic reticulum stress-associated molecular signature across cardiovascular-kidney-metabolic syndrome stages
- Exogenous L6 myotube mitochondrial transplantation attenuates hypertrophy and elicits a unique proteomic signature in phenylephrine-treated H9C2 cardiomyocytes
- Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases
- iPSC-Derived Myotubes from ME/CFS Patients Reveal Signature Genes, Isoforms and Pathways with Drug Repurposing Potential
BibTeX
@misc{baechle2026immunoproteomic,
title = {{Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients}},
author = {J. J. Baechle and J. Arthur and K. Nguyen and F. Wu and M. Fuentealba and K. U. Knowlton and S. Knight and B. Horne and N. Sayed and H. Maecker and D. A. Winer and N. Barzilai and M. M. Davis and F. Haddad and D. Furman},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.27.762320},
url = {https://www.biorxiv.org/content/10.64898/2026.10.27.762320v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients
AU - J. J. Baechle
AU - J. Arthur
AU - K. Nguyen
AU - F. Wu
AU - M. Fuentealba
AU - K. U. Knowlton
AU - S. Knight
AU - B. Horne
AU - N. Sayed
AU - H. Maecker
AU - D. A. Winer
AU - N. Barzilai
AU - M. M. Davis
AU - F. Haddad
AU - D. Furman
PY - 2026
DA - 2026/10/27
PB - bioRxiv
DO - 10.64898/2026.10.27.762320
UR - https://www.biorxiv.org/content/10.64898/2026.10.27.762320v1
AB - Despite advances in clinical care, cardiovascular disease (CVD) remains the leading cause of disability and mortality worldwide. While age alone is a primary risk factor for CVD, accumulating evidence suggests the immune system influences the initiation and progression of CVD pathophysiology, particularly in heart failure with preserved ejection fraction (HFpEF) and atherosclerotic CVD (ASCVD). Here, using two independent cohorts of older adults, we develop a thirty-protein signature of age based on serum immune proteomics, which correlates with HFpEF and ASCVD risk and mortality (Immuno-Proteomic Age of Cardiovascular Etiology, iPACE). We find aging-related circulating immune proteins associated with ASCVD and HFpEF-specific resilience and susceptibility that may be used as potential prognostic, diagnostic, or therapeutic targets.
ER -